Rallybio Corporation
NASDAQ:RLYB
0.95 (USD) • At close December 20, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
2023 | 2022 | 2021 | 2020 | 2019 | |
---|---|---|---|---|---|
Revenue
| 0 | 0 | 0 | 0 | 0 |
Cost of Revenue
| 0.15 | 0.167 | 0.109 | 0.062 | 0.026 |
Gross Profit
| -0.15 | -0.167 | -0.109 | -0.062 | -0.026 |
Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 |
Reseach & Development Expenses
| 53.544 | 40.689 | 26.909 | 17.63 | 11.366 |
General & Administrative Expenses
| 25.388 | 27.195 | 18.739 | 7.673 | 6.276 |
Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 |
SG&A
| 25.388 | 27.195 | 18.739 | 7.673 | 6.276 |
Other Expenses
| 0 | 0.342 | 0.096 | 0.241 | 0.024 |
Operating Expenses
| 78.932 | 67.884 | 45.648 | 25.303 | 17.642 |
Operating Income
| -78.932 | -67.884 | -45.648 | -25.303 | -17.642 |
Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 |
Total Other Income Expenses Net
| 4.368 | 2.305 | 0.14 | 0.363 | 0.182 |
Income Before Tax
| -74.564 | -65.579 | -45.508 | -24.94 | -17.46 |
Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 |
Income Tax Expense
| -2.041 | 0.908 | 1.502 | -0.015 | 0.166 |
Net Income
| -74.564 | -66.487 | -47.01 | -24.925 | -17.626 |
Net Income Ratio
| 0 | 0 | 0 | 0 | 0 |
EPS
| -1.84 | -2.09 | -1.46 | -0.78 | -0.55 |
EPS Diluted
| -1.84 | -2.09 | -1.46 | -0.78 | -0.55 |
EBITDA
| -72.373 | -65.412 | -45.389 | -24.829 | -17.395 |
EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 |